NICE's Nod To Soliris Tainted By Request For R&D Cost Data
This article was originally published in The Pink Sheet Daily
The U.K.s NICE is on the verge of recommending Alexion's Soliris for aHUS despite an astronomic price; but its request for R&D cost data will alarm the drug industry.
You may also be interested in...
Risk management program for Alexion’s orphan drug eculizumab appears to be succeeding, but what does FDA need to see to make it less burdensome?
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.